Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma
| Status: | Completed |
|---|---|
| Conditions: | Liver Cancer, Cancer, Endocrine, Thyroid Cancer |
| Therapuetic Areas: | Endocrinology, Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 8/31/2018 |
| Start Date: | October 2011 |
| End Date: | August 2018 |
Phase I Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib, a VEGFR/PDGFR/Raf Inhibitor, and GSK1120212, a MEK Inhibitor, in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer, Soft Tissue Sarcoma, and Cholangiocarcinoma
The purpose of this study is to determine the safety and toxicity of the combination of
pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated
dose (MTD) of this combination for phase II study.
pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated
dose (MTD) of this combination for phase II study.
Inclusion Criteria:
- Dose escalation cohort for all solid tumors is closed to enrollment.
- Expansion cohorts: Soft-tissue sarcoma, cholangiocarcinoma, and differentiated thyroid
cancer (DTC) cohorts are closed to enrollment. Patients in the DTC cohort must have
disease that is able to be biopsied.
- Must have measurable disease.
- Tumor progression in the 6-month period prior to study drug initiation.
- DTC patients: must have radioiodine non-avid lesions, OR radioiodine avid lesions that
have not responded to treatment with radioactive iodine.
- ECOG performance status less than or equal to 1.
- Life expectancy >3 months.
- Blood pressure <140 mmHg and <90 mmHg.
- LVEF is >= 50%
- Must be able to swallow pills.
Exclusion Criteria:
- Chemotherapy, radiotherapy, other investigational therapy, or major surgery within 4
weeks.
- Sarcoma and cholangiocarcinoma ONLY: Prior VEGF-targeted TKI therapy.
- Pregnant or currently breastfeeding.
- Unresolved toxicity greater than grade 1.
- Evidence of active hepatitis or HIV.
- Significant cardiovascular disease.
- Taking medications known to be strong inducers or inhibitors of CYP3A enzymes.
- Clinically significant gastrointestinal abnormalities that may increase the risk for
gastrointestinal bleeding.
- History of gastrointestinal condition causing malabsorption or obstruction.
- Cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism
or untreated deep vein thrombosis (DVT) within past 6 months.
- Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels that
increase risk of pulmonary hemorrhage.
- Hemoptysis within 6 months of starting treatment.
- History of retinal vein occlusion (RVO) or central serous retinopathy (CSR), or
predisposing factors to RVO or CSR as assessed by ophthalmic exam.
- Known brain mets that are not stable for at least 8 weeks prior to treatment, or
patient is on glucocorticoids for brain mets.
We found this trial at
2
sites
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins The name Johns Hopkins has become synonymous...
Click here to add this to my saved trials
Click here to add this to my saved trials